MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Giancarlo Comi; Stuart D Cook; Gavin Giovannoni; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony C Hamlett; Vissia Viglietta; Steven J Greenberg

doi:10.1007/s00415-012-6775-0

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Giancarlo Comi, Stuart D Cook, Gavin Giovannoni, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony C Hamlett, Vissia Viglietta, Steven J Greenberg

Department of Clinical Medicine

26 Citations (Scopus)

Abstract

We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p

Original language	English
Journal	Journal of Neurology
ISSN	0340-5354
DOIs	https://doi.org/10.1007/s00415-012-6775-0
Publication status	Published - Apr 2013

Access to Document

10.1007/s00415-012-6775-0

Cite this

@article{40011d8cf57542a2af40f500161bb913,

title = "MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study",

abstract = "We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p ",

author = "Giancarlo Comi and Cook, {Stuart D} and Gavin Giovannoni and Kottil Rammohan and Peter Rieckmann and S{\o}rensen, {Per Soelberg} and Patrick Vermersch and Hamlett, {Anthony C} and Vissia Viglietta and Greenberg, {Steven J}",

year = "2013",

month = apr,

doi = "10.1007/s00415-012-6775-0",

language = "English",

journal = "Deutsche Zeitschrift fur Nervenheilkunde",

issn = "0939-1517",

publisher = "Springer Medizin",

}

TY - JOUR

T1 - MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

AU - Comi, Giancarlo

AU - Cook, Stuart D

AU - Giovannoni, Gavin

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony C

AU - Viglietta, Vissia

AU - Greenberg, Steven J

PY - 2013/4

Y1 - 2013/4

N2 - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p

AB - We herein provide a comprehensive assessment of magnetic resonance imaging (MRI) outcomes from CLARITY, a 96-week, double-blind study demonstrating significant clinical and MRI improvements in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets. Patients with RRMS were randomized 1:1:1 to annual short-course therapy with cladribine tablets cumulative dose 3.5 or 5.25 mg/kg or placebo. MRI endpoints included mean number of T1 gadolinium-enhancing (Gd+), active T2 and combined unique (CU) lesions/patient/scan. MRI-measured disease activity was significantly reduced in both cladribine tablets groups versus placebo. The proportion of patients with no active lesions at study end was: T1 Gd+ lesions: 86.8 and 91.0 versus 48.3 % (p

U2 - 10.1007/s00415-012-6775-0

DO - 10.1007/s00415-012-6775-0

M3 - Journal article

C2 - 23263473

SN - 0939-1517

JO - Deutsche Zeitschrift fur Nervenheilkunde

JF - Deutsche Zeitschrift fur Nervenheilkunde

ER -

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

Abstract

Access to Document

Fingerprint

Cite this